

Correction: KRAS Inhibitor Resistance in *MET*-Amplified *KRAS*^{G12C} Non-Small Cell Lung Cancer Induced By RAS- and Non-RAS-Mediated Cell Signaling Mechanisms



Shinichiro Suzuki, Kimio Yonesaka, Takeshi Teramura, Toshiyuki Takehara, Ryoji Kato, Hitomi Sakai, Koji Haratani, Junko Tanizaki, Hisato Kawakami, Hidetoshi Hayashi, Kazuko Sakai, Kazuto Nishio, and Kazuhiko Nakagawa

In the original version of this article (1), the “Crizotinib” label in Fig. 4F is incorrect; the label should be “Selumetinib”. The error has been corrected in the latest online HTML and PDF versions of the article. The publisher regrets the error.

Reference

1. Suzuki S, Yonesaka K, Teramura T, Takehara T, Kato R, Sakai H, et al. KRAS inhibitor resistance in *MET*-amplified *KRAS*^{G12C} non-small cell lung cancer induced by RAS- and non-RAS-mediated cell signaling mechanisms. *Clin Cancer Res* 2021;27:5697–707.

Published online January 19, 2022.

Clin Cancer Res 2022;28:428

doi: 10.1158/1078-0432.CCR-21-4240

©2022 American Association for Cancer Research